Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Mineralys Therapeutics, Inc.

NASDAQ: MLYS · Life Sciences · 6 alerts · CIK 1933414

Share price
$14.53Close, Nov 16
Market cap
$1.29B
Shares outstanding
88.56MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Mineralys Therapeutics, Inc. filings on SEC EDGAR ↗

4:08 PM ET 8-K
M&A Deal

Mineralys Therapeutics M&A Deal with Tanabe Pharma Corporation

Mineralys Therapeutics entered into a Termination Agreement and Payment Obligation Agreement with Tanabe Pharma Corporation to acquire full ownership of the intellectual property for lorundrostat. The agreements terminate the existing license and assign the patents and know-how directly to Mineralys, while maintaining existing commercial milestone obligations of up to $265 million. This transition from licensee to owner removes potential change-of-control payment triggers and consolidates the company's control over its lead drug candidate.

Counterparty
Tanabe Pharma Corporation

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.